Participated · Series C · May 2026

Accro Bioscience is a clinical-stage biotech developing first- and best-in-class small-molecule therapeutics that target regulatory cell death pathways for inflammatory and immune-mediated diseases. Its lead asset, AC-101, is a selective RIPK2 inhibitor being developed for moderate-to-severe ulcerative colitis and has completed Phase I studies in healthy volunteers in Australia and China, plus a Phase Ib/IIa proof-of-concept study in Chinese patients. The company has received IND clearance from the U.S. FDA to proceed with Phase II studies of AC-101. Accro announced a $50 million Series C to fund a Phase IIb trial of AC-101 and to advance other pipeline candidates. The company operates out of New York and Suzhou and describes a multi-asset pipeline originating from a proprietary drug discovery platform focused on regulatory cell death and inflammation. Ongoing clinical progress and the new financing position Accro to advance global development of its lead and follow-on programs.

Participated · Series A · Jun 2022

Mila provides on-demand, vetted, crowdsourced technical support and installation services through a network of trained technicians and its Mila Academy. Since 2016 it has expanded from Switzerland into Germany, Austria, France, and the UK, and maintains offices in Berlin and Zürich with a new London location. The company reports over 11,000 trained technicians and more than 40 enterprise/brand partners, and says it experienced over 300% growth in Germany in 2021. Mila continues to serve Swisscom and enterprise customers including Amazon, Otto, BOSCH, and Google. The company offers installation, configuration, and integration services and plans to introduce EV charging station installations in Germany and the UK in Q2. With the MATTER IoT standard release targeted for fall 2022, Mila positions itself to address connected-device interoperability challenges for global brands. Mila is a location-based mobile marketplace for tasks and products that lets people find, discover and buy services from people in their neighbourhood or earn extra cash by offering their own services. It operates on mobile web and web and is currently revamping its iOS and Android apps. Mila is a spin-off from CoreSystems, a Swiss mobile enterprise platform provider backed by SAP, and also has operations in Zurich and Berlin. The company has a global footprint and is concentrating on emerging markets, targeting cities such as Shanghai and Jakarta. Mila raised $3.22 million (€2.46 million) from private Swiss and German technology investors and will use the funding to expand in Indonesia and China. Named investors include Peter Zencke and Adrian Bult.

Participated · Seed · Apr 2022

Unifimoney provides a digital wealth management platform that enables community banks and credit unions to offer investment services to their customers. The platform supports trading of more than 70 cryptocurrencies, passive and active investing in thousands of stocks and ETFs, and trading in precious metals including gold, silver and platinum. It integrates with financial-institution core providers such as Jack Henry & Associates and Q2. The company plans to use new funding to expand coverage of alternative assets including collectables, sports memorabilia and NFTs, and to offer a full suite of retirement accounts with both traditional and alternative-asset IRAs. Roadmap items also include an investment-rewards credit card that would let bank and credit-union customers earn points redeemable for investable assets like crypto, stocks and gold. The company was founded in 2019 and is led by CEO Ben Soppitt and CTO Ed Cortis.

Participated · Series A · Feb 2022

Parade is a San Francisco-based software platform that provides truckload capacity management to freight brokers, driving carrier access and digital transformation. Led by CEO and Co-Founder Anthony Sutardja, the platform helps users manage relationships, increase truckload capacity, and re-utilize carriers to find the right truck at the best price at the right time. The company raised $17M in funding to support growth and product development. Parade intends to use the proceeds to develop and enhance products that accelerate brokers’ ability to transact freight at scale. Its roadmap includes using Generative AI to turn conversations into freight bookings and expanding integrations with transportation management systems, load boards, rating benchmarks, visibility platforms, and compliance solutions. Parade provides an AI-enabled Truckload Capacity Management Platform that layers on top of a freight broker’s existing systems, such as a Transportation Management System (TMS), to help brokers find availability, book trucks online, and digitally transact loads. Over the past year the company brought its core Capacity Management product to market for freight brokers. Parade’s platform is designed to charge a broker’s capabilities to find and transact truckload capacity and to strengthen connectivity with third-party partners. Customers include major brokerages such as Armstrong Transport Group, Schneider, and Worldwide Express. The company plans to use its recent funding to accelerate digital adoption, expand product capabilities, grow its team, and deepen connectivity across its partner ecosystem. Parade was founded in 2015 in San Francisco.

Participated · Seed · Jun 2021

OnCusp Therapeutics is a biopharma company focused on translating preclinical oncology innovation into clinically validated treatments. Its lead asset, CUSP06, is a CDH6‑targeting antibody‑drug conjugate with preclinical data showing increased potency, bystander effect, linker stability, and potential to overcome drug resistance. CUSP06 obtained FDA IND clearance in 3Q 2023 and is planned for a first‑in‑human Phase I study in the U.S. The company secured an oversubscribed $100 million Series A to advance CUSP06 toward clinical proof‑of‑concept and to expand its portfolio and team. OnCusp has global rights (outside China) to CUSP06 from Multitude Therapeutics and lists WuXi XDC as the CMC partner for the program. Since its establishment in April 2021, OnCusp has raised $139 million in total. OnCusp focuses on advancing preclinical oncology candidates—including bispecific antibodies, antibody-drug conjugates (ADCs), and small molecules—toward clinical proof-of-concept. The company in-licenses preclinical drug candidates from the U.S., China and other regions and advances them into global early clinical development. OnCusp aims to out-license assets to multinational pharmaceutical companies after establishing clinical POC. The founding team has deep experience in business development and oncology translational and clinical development. The company opened operations in New York and Shanghai and is building a portfolio of high-potential oncology assets. OnCusp completed a $25 million seed financing to support pipeline development, R&D programs, day-to-day operations, and talent acquisition.